Correct me if I'm wrong, but isn't AVXL the company that had a total compensation package for their CEO of almost $20M over the past 4 years?
That's an OBSCENE compensation package for a CEO in a development-stage biotech. All development-stage bios need to raise precious cash, and that must hurt their shareholders to see such dilution (cash and shares) handed to their CEO.
That's your opinion. In my opinion if you can't re grow, repair, restore the synapses then you are not going to be an effective treatment in reversing the disease. I'm not looking at nibbling around the edges. I'm looking for improvement. So far that's what we've seen
Market Data 
Markets 
AI
